CA3246949A1 - NEW ANTI-FGFR2 ANTIBODIES - Google Patents
NEW ANTI-FGFR2 ANTIBODIESInfo
- Publication number
- CA3246949A1 CA3246949A1 CA3246949A CA3246949A CA3246949A1 CA 3246949 A1 CA3246949 A1 CA 3246949A1 CA 3246949 A CA3246949 A CA 3246949A CA 3246949 A CA3246949 A CA 3246949A CA 3246949 A1 CA3246949 A1 CA 3246949A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2022/083269 | 2022-03-28 | ||
| CN2022083269 | 2022-03-28 | ||
| PCT/CN2023/084213 WO2023185778A1 (en) | 2022-03-28 | 2023-03-28 | Novel anti-fgfr2 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3246949A1 true CA3246949A1 (en) | 2023-10-05 |
Family
ID=88199423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3246949A Pending CA3246949A1 (en) | 2022-03-28 | 2023-03-28 | NEW ANTI-FGFR2 ANTIBODIES |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4499701A4 (https=) |
| JP (1) | JP2025513745A (https=) |
| KR (1) | KR20250042203A (https=) |
| CN (1) | CN119110806A (https=) |
| AU (1) | AU2023243773A1 (https=) |
| CA (1) | CA3246949A1 (https=) |
| IL (1) | IL315970A (https=) |
| MX (1) | MX2024011805A (https=) |
| WO (1) | WO2023185778A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202600596A (zh) * | 2024-03-04 | 2026-01-01 | 大陸商杭州中美華東製藥有限公司 | 抗ＦＧＦＲ２ｂ抗體、其抗體藥物偶聯物及其用途 |
| CN118772279B (zh) * | 2024-06-28 | 2025-03-25 | 北京普利米特生物科技有限公司 | 抗FGFR2b抗体或其抗原结合片段及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014089193A1 (en) * | 2012-12-04 | 2014-06-12 | Aveo Pharmaceuticals, Inc. | Anti-fgfr2 antibodies |
| PH12021552742A1 (en) * | 2013-08-01 | 2022-05-23 | Five Prime Therapeutics Inc | Afucosylated anti-fgfr2iiib antibodies |
| KR20220019839A (ko) * | 2013-10-08 | 2022-02-17 | 다이이찌 산쿄 가부시키가이샤 | 항 fgfr2 항체와 타제의 조합 |
| EP3287522A4 (en) * | 2015-04-20 | 2019-03-27 | Daiichi Sankyo Company, Limited | DETECTION OF FGFR2 |
| US20220010020A1 (en) * | 2018-10-05 | 2022-01-13 | Five Prime Therapeutics, Inc. | Anti-FGFR2 Antibody Formulations |
| CA3160810A1 (en) * | 2019-12-24 | 2021-07-01 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel anti-fgfr2b antibodies |
| MX2022007961A (es) * | 2019-12-24 | 2022-07-12 | Dizal Jiangsu Pharmaceutical Co Ltd | Nuevos anticuerpos anti-fgfr2b. |
| US20230052256A1 (en) * | 2019-12-24 | 2023-02-16 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel anti-fgfr2b antibodies |
-
2023
- 2023-03-28 AU AU2023243773A patent/AU2023243773A1/en active Pending
- 2023-03-28 CN CN202380031311.1A patent/CN119110806A/zh active Pending
- 2023-03-28 JP JP2024557632A patent/JP2025513745A/ja active Pending
- 2023-03-28 CA CA3246949A patent/CA3246949A1/en active Pending
- 2023-03-28 WO PCT/CN2023/084213 patent/WO2023185778A1/en not_active Ceased
- 2023-03-28 EP EP23778143.0A patent/EP4499701A4/en active Pending
- 2023-03-28 IL IL315970A patent/IL315970A/en unknown
- 2023-03-28 KR KR1020247035207A patent/KR20250042203A/ko active Pending
-
2024
- 2024-09-25 MX MX2024011805A patent/MX2024011805A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024011805A (es) | 2024-11-08 |
| WO2023185778A1 (en) | 2023-10-05 |
| CN119110806A (zh) | 2024-12-10 |
| EP4499701A4 (en) | 2026-02-25 |
| IL315970A (en) | 2024-11-01 |
| WO2023185778A9 (en) | 2023-11-02 |
| JP2025513745A (ja) | 2025-04-30 |
| KR20250042203A (ko) | 2025-03-26 |
| EP4499701A1 (en) | 2025-02-05 |
| AU2023243773A1 (en) | 2024-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022050522A (ja) | 癌の治療のための併用療法 | |
| US11155625B2 (en) | Anti-PD-1 antibodies and uses thereof | |
| US12180281B2 (en) | Anti-PD-1 antibodies and methods of treating cancer | |
| BRPI0714893A2 (pt) | anticorpo monoclonal isolado ou uma porÇço de ligaÇço ao seu antÍgeno, um fragmento de anticorpo, um anticorpo mimÉtico, imunoconjugado, composiÇço molÉcula de Ácido nuclÉico isolada, vetor de expressço, cÉlula hospedeira, mÉtodo para preparar um anticorpo anti-bmp2 ou anti-bmp4, mÉtodo para tratar ou prevenir uma doenÇa associada com formaÇço àssea normal e ossificaÇço, hibridoma e metodo para preparar o anticorpo | |
| JP2022516916A (ja) | 抗ｔｎｆｒｓｆ９抗体及びその使用 | |
| WO2023185778A1 (en) | Novel anti-fgfr2 antibodies | |
| KR20220005058A (ko) | 항-bcma 항체 접합체, 그를 포함하는 조성물, 및 그의 제조 및 사용 방법 | |
| WO2024199362A1 (en) | Novel anti-FGFR2 antibodies | |
| TW202428608A (zh) | 抗b7h3抗體以及其使用方法 | |
| JP2026503246A (ja) | 抗ＣＤ７９ｂ抗体及びその使用 | |
| EA052794B1 (ru) | Новые антитела против fgfr2 | |
| HK40114936A (zh) | 新型抗fgfr2抗体 | |
| WO2024175020A1 (en) | Anti-il2ra antibodies and uses thereof | |
| JP2026500752A (ja) | 抗ｂ７ｈ３抗体及びその使用方法 | |
| CN121152808A (zh) | 抗ccr8抗体和抗ccr8/ctla4双特异性抗体 | |
| HK40050386A (en) | Anti-pd-1 antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240926 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240926 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241010 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241010 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241011 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241118 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241213 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20241213 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250304 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250304 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250304 |